Recent advances in antiemetics: new formulations of 5HT₃-receptor antagonists.

54 In a post hoc subgroup analysis of the 589 patients (65%) receiving AC-based HEC, at least 98% of whom were women, delayed-phase CR rates showed a trend favoring the GERSC arm (64%) over the ondansetron arm (56%). 95 A similar trend was found in the subgroup of 252 patients scheduled to receive cisplatin, where delayed-phase CR rates were numerically higher in the GERSC arm (65%) than in the ondansetron arm (55%). 96 These subgroup findings were consistent with the overall population, although the analyses were not powered to show a significant difference between groups.

also in 53,322 other papers